Bring Your Questions About Device Detected AF to the Experts: Latest Insights from the NOAH and ARTESIA Trials-Bring Your Questions About Device Detected AF to the Experts: Latest Insights from the NOAH and ARTESIA Trials

Bring Your Questions About Device Detected AF to the Experts: Latest Insights from the NOAH and ARTESIA Trials

Video Transcription

Video Summary

The session focused on subclinical atrial fibrillation and its implications, primarily drawing insights from the ARTESIA and NOAH trials. Dr. Jeff Healy presented on the ARTESIA trial, which examined the use of apixaban in patients with subclinical atrial fibrillation. The trial found a 37% reduction in stroke and systemic embolism risk, but also a 36% increase in major bleeding with apixaban use. The study highlighted the complexities in determining which patients benefit most from anticoagulation, emphasizing higher stroke prevention benefit in patients with a CHA2DS2-VASc score greater than four.<br /><br />Dr. Blomstrom-Lundquist shared findings from the NOAH trial, which also explored anticoagulation in patients with device-detected AF, noting that duration of AF episodes did not significantly impact anticoagulation’s effectiveness, nor did a prior history of stroke.<br /><br />A series of case presentations illustrated real-world complexities in managing subclinical AF, emphasizing the challenges of weighing stroke risk reduction against bleeding hazard. Discussions emphasized the nuanced decision-making required, especially in light of new findings and the need for patient-centered care. The session underscored gaps in current understanding and the importance of tailored strategies for AF management.

Keywords

subclinical atrial fibrillation

ARTESIA trial

NOAH trial

apixaban

stroke prevention

anticoagulation

CHA2DS2-VASc score

bleeding risk

patient-centered care